Corporació Sanitària Parc Taulí

Running trials

• Not yet recruiting

  Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Renal Cell Carcinoma

  NCT07593040· Phase 2· Vall d'Hebron Institute of Oncology· Source

• Recruiting

  A Study of RO7871996 in Participants with Systemic Lupus Erythematosus

  2026-527221-35-00· Phase 1/2· F. Hoffmann-La Roche AG· Source

• Recruiting

  A clinical trial to assess the efficacy and safety of ontunisertib compared to placebo in patients with fibrostenosing Crohn’s disease

  2026-525197-19-00· Phase 2· Agomab Spain S.L.U.· Source

• Recruiting

  A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)

  NCT07919678· Phase 3· Pfizer· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)

  NCT07541170· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Study evaluating the efficacy and safety of daridorexant in patients with major depressive disorder and insomnia.

  2025-524794-16-00· Phase 4· Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL· Source

• Recruiting

  Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)

  NCT07817875· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma

  NCT07476326· Phase 1· Biocon Biologics UK PLC· Source

• Not yet recruiting

  iSGLT2 in permanent atrial fibrillation, heart failure with preserved ejection fraction and intermediate NT-proBNP values: randomized clinical trial

  2026-525968-18-00· Phase 4· Institut D Investigacio Sanitaria Pere Virgili· Source

• Not yet recruiting

  The Efficacy and Safety Study of 2107 Injection in Subjects With Mild to Moderate Knee Osteoarthritis

  NCT07746843· BioRegen Biomedical (Changzhou) Co., Ltd· Source

• Recruiting

  Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer

  NCT07564141· Phase 3· Genmab· Source

• Recruiting

  A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease

  NCT07737743· Phase 2· Novartis Pharmaceuticals· Source

• Recruiting

  A double-dummy, double-blind, randomized, active controlled, two-way cross-over study with 12-week treatment duration per period, to evaluate the efficacy and safety of QVM149 (indacaterol acetate / glycopyrronium bromide / mometasone furoate) compared to salmeterol xinafoate/fluticasone propionate in children from 12 years to less than 18 years of age with asthma.

  2022-502365-26-00· Phase 3· Novartis Pharma AG· Source

• Recruiting

  A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  NCT07497087· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A study to investigate how well and safe a trial drug called AZD1163, administered as an injection, works in improving symptoms and inflammation in adult participants with moderately to severely active rheumatoid arthritis.

  2025-522076-85-00· Phase 2· AstraZeneca AB· Source

• Recruiting

  A Study to Evaluate Targeted Therapies for Patients with Rheumatoid Arthritis

  2025-523127-21-00· Phase 1· AbbVie Deutschland GmbH & Co. KG· Source

• Recruiting

  Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden

  NCT07621809· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus

  2025-523670-17-00· Phase 3· AstraZeneca AB· Source

• Recruiting

  An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS

  NCT07665437· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)

  NCT07631637· Phase 2· Regeneron Pharmaceuticals· Source

• Recruiting

  A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed

  NCT07650916· Phase 3· ViiV Healthcare· Source

• Recruiting

  Diagnostic Value of Oropharyngeal Suction and Effect of Respiratory Physiotherapy on the Detection of Microorganisms in the Pediatric Patient

  NCT07903792· Corporacion Parc Tauli· Source

• Not yet recruiting

  Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis

  NCT07018206· Phase 4· CARE ARTHRITIS LTD.· Source

• Not yet recruiting

  Immunosuppressant Discontinuation in Elderly Patients With Ulcerative Colitis And Long-term Remission

  NCT07248644· Phase 4· Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa· Source

• Recruiting

  Home tDCS for the Treatment of Major Depression.

  NCT07510880· Ionclinics & Deionic SL· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy

  NCT07493265· Phase 2· Eisai Inc.· Source

• Recruiting

  Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis

  NCT07286058· Phase 3· Takeda· Source

• Recruiting

  AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF

  NCT07194382· Phase 2· Avalyn Pharma Inc.· Source

• Not yet recruiting

  A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (PsA)

  2025-522471-28-00· Phase 3· MoonLake Immunotherapeutics AG· Source

• Recruiting

  Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy

  NCT07340164· Phase 2· Yonsei University· Source

• Recruiting

  A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis

  NCT07047690· Phase 2· Galderma R&D· Source

• Recruiting

  A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

  NCT07409272· Phase 3· Astellas Pharma Global Development, Inc.· Source

• Recruiting

  A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)

  NCT07202546· Phase 2· ViiV Healthcare· Source

• Recruiting

  A PK study to compare JPB898 (proposed nivolumab biosimilar) and US-licensed Opdivo® in participants with resected stage IIB, IIC, or III melanoma in the adjuvant setting

  2025-521919-39-00· Phase 1· H e x a l AG· Source

• Recruiting

  RANDOMISED, MULTICENTRE, DOUBLE-BLIND CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF MONTELUKAST VS. PLACEBO IN PATIENTS WITH EROSIVE/INFLAMMATORY OSTEOARTHRITIS OF THE HANDS. MOTHER Study.

  2025-521802-17-00· Phase 3· Farmalider S.A.· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder

  NCT07227454· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Randomised, Multicentre, Multinational, Double-Blind Integrated Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 (Proposed Nivolumab Biosimilar) Versus EU-/US-Opdivo in Subjects With Previously Untreated Advanced (Unresectable or Metastatic) Melanoma (LEON Study)

  2025-521562-95-00· Phase 3· Mabxience Research S.L.· Source

• Recruiting

  A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

  NCT07155187· Phase 2/3· AbbVie· Source

• Recruiting

  A study to find how well budoprutug (TNT119) works and how safe it is in participants with Systemic Lupus Erythematosus

  2024-520385-57-01· Phase 1· Climb Bio Inc.· Source

• Active, not recruiting

  Study of GS-0151 in Participants With Rheumatoid Arthritis

  2024-516520-34-00· Phase 1· Gilead Sciences Inc.· Source

• Recruiting

  EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial-1)

  2025-521315-39-00· Phase 1· Grey Wolf Therapeutics Limited· Source

• Recruiting

  ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

  NCT07173751· Phase 3· BioNTech SE· Source

• Recruiting

  A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)

  NCT07194850· Phase 2/3· argenx· Source

• Active, not recruiting

  A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)

  NCT07176390· Phase 2· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

  NCT06919965· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

  NCT07011719· Phase 3· Arcus Biosciences, Inc.· Source

• Recruiting

  A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

  NCT06952803· Phase 3· AstraZeneca· Source

• Recruiting

  SAKK 08/23: Addition of Darolutamide to first line treatment of mCRPC: a randomized open label phase II trial

  2024-512132-29-00· Phase 2· Swiss Group for Clinical Cancer Research· Source

• Recruiting

  A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

  NCT06911502· Phase 3· Celgene· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Boehringer Ingelheim· Source

Showing 50 of 185.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Prostate cancer11 recruiting
• Lung cancer7 recruiting
• Bladder cancer6 recruiting
• Lupus (SLE)6 recruiting
• Crohn's disease5 recruiting
• Depression5 recruiting
• Kidney cancer4 recruiting
• Liver cirrhosis4 recruiting
• Obesity4 recruiting
• Ankylosing spondylitis3 recruiting
• Asthma3 recruiting
• Atrial fibrillation3 recruiting
• Diffuse large B-cell lymphoma3 recruiting
• Fatty liver disease (MASLD/MASH)3 recruiting
• Follicular lymphoma3 recruiting
• Melanoma3 recruiting
• Osteoarthritis3 recruiting
• Ovarian cancer3 recruiting
• Psoriatic arthritis3 recruiting
• Systemic sclerosis (scleroderma)3 recruiting
• Ulcerative colitis3 recruiting
• Colorectal cancer2 recruiting
• Pancreatic cancer2 recruiting
• Psoriasis2 recruiting
• Rheumatoid arthritis2 recruiting
• Sjögren's disease2 recruiting
• Triple-negative breast cancer2 recruiting
• Bronchiectasis1 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
• Cystic fibrosis1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Endometrial cancer1 recruiting
• Endometriosis1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Heart failure1 recruiting
• Hidradenitis suppurativa1 recruiting
• High blood pressure1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Immune thrombocytopenia (ITP)1 recruiting
• Insomnia1 recruiting
• Mesothelioma1 recruiting
• Migraine1 recruiting
• Narcolepsy1 recruiting
• Primary biliary cholangitis1 recruiting
• Sarcoma1 recruiting
• Schizophrenia1 recruiting
• Stroke1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Recruiting

  Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  NCT07214779· Phase 3· Incyte Corporation· Source

• Completed

  A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis

  NCT07225829· Phase 2· 4Moving Biotech· Source

• Active, not recruiting

  Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

  NCT06726265· Phase 3· Immutep S.A.S.· Source

• Completed

  Functional Connectome in Prader-Willi Syndrome: Neuroimaging and AI to Assess Therapeutic Impact

  NCT06900335· Corporacion Parc Tauli· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis

  NCT06754462· Phase 2· Immunovant Sciences GmbH· Source

• Completed

  A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and an Open- labeled Long-term Extension Treatment with Aticaprant

  2024-511557-21-00· Phase 3· Janssen Cilag International· Source

• Completed

  A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Abiprubart in Participants with Sjögren’s Disease

  2024-512986-15-00· Phase 2· Kiniksa Pharmaceuticals GmbH· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis

  NCT06624228· Phase 3· UCB Biopharma SRL· Source

• Completed

  A Phase 1b, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Safety, Engraftment, and Initial Signs of Clinical Activity of MB310 in Patients with Active, Mild to Moderate Ulcerative Colitis (COMPOSER-1)

  2023-507376-50-00· Phase 1· Microbiotica Limited· Source

• Completed

  A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.

  NCT06383403· Phase 3· Ipsen· Source

• Completed

  A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer

  NCT06395753· Phase 2· Debiopharm International SA· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

  NCT06104124· Phase 3· Amgen· Source

• Completed

  Multicenter Phase 2 study to evaluate the efficacy and safety of Cetuximab in combination with Encorafenib plus Binimetinib as induction treatment in BRAF (V600E) mutated MSS, initially resectable or potentially resectable advanced colorectal cancer: CEBBRA study.

  2022-502413-29-00· Phase 2· Asociacion Grupo Tratamiento De Tumores Digestivos· Source

• Active, not recruiting

  A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06260163· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A randomized, multi-centre, double-blind, phase II clinical trial of dose finding of Montelukast in patients with erosive osteoarthritis of the hands. HOME study.

  2023-506137-30-00· Phase 2· Farmalider S.A.· Source

• Active, not recruiting

  MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06132256· Phase 2· Syndax Pharmaceuticals· Source

• Completed

  A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis

  NCT06073093· Phase 2· Sanofi· Source

• Completed

  Living With Long COVID: LONGCOVID-EXPERIENCE

  NCT06118112· Corporacion Parc Tauli· Source

• Completed

  A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke

  NCT05953480· Phase 2· Shionogi· Source

• Completed

  A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF

  NCT05911360· Phase 3· ViiV Healthcare· Source

• Completed

  A study to evaluate if aticaprant added to a current antidepressant and given up to one year is safe and would help improve depression.

  2023-508163-74-00· Phase 3· Janssen Cilag International· Source

• Completed

  A Study of Two Dose Levels of Vobramitamab Duocarmazine in Participants with Metastatic Castration-resistant Prostate Cancer (TAMARACK)

  NCT05551117· Phase 2· Macrogenics Inc.· Source

• Completed

  A study in metastatic breast cancer patients receiving eftilagimod alpha or placebo in combination with a standard chemotherapy (paclitaxel)

  NCT05747794· Phase 2/3· Immutep· Source

• Completed

  A Two-part Study to Investigate the Effects in Adults of Two Doses of Golexanolone in Patients With Primary Biliary Cholangitis (PBC) With Fatigue and Cognitive Dysfunction

  NCT07304843· Phase 1/2· Umecrine Cognition AB· Source

• Completed

  Study of an Early Parenting Intervention for Children With Genetic Abnormalities and Mental Health Problems

  NCT06125093· Fundació Sant Joan de Déu· Source

• Completed

  A Open-label Study to Evaluate the Efficacy, Safety, Tolerability of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis

  NCT04781543· Phase 2· Horizon Therapeutics Ireland Designated Activity Company· Source

• Completed

  A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)

  NCT05694260· Phase 2· Esperion Therapeutics, Inc.· Source

• Completed

  Phase 2b Study of GSK4532990 in Adults With NASH

  NCT05583344· Phase 2· GlaxoSmithKline· Source

• Completed

  Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)

  NCT05630820· Phase 3· GlaxoSmithKline· Source

• Completed

  Impact of Therapeutic Intervention on Quality of Life in Patients With Ulcerative Colitis

  NCT05271773· Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa· Source

• Terminated

  A Proof-of-concept Study to Examine QUC398 in Participants With Knee OA

  NCT05462990· Phase 2· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)

  NCT05170204· Phase 3· Hoffmann-La Roche· Source

• Completed

  Comparison of a Single RTX-GRT7039 and Placebo Intra-articular Injection for Pain Associated With Osteoarthritis of the Knee

  NCT05449132· Phase 3· Grünenthal GmbH· Source

• Completed

  Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome

  NCT05322096· Phase 2· Gedeon Richter Plc.· Source

• Completed

  Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

  NCT05350072· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Phase II trial of Pembrolizumab and Olaparib in homologous-recombination deficient (HRD) advanced colorectal cancer (CRC).

  NCT05201612· Phase 2· Grupo Espanol Multidisciplinar En Cancer Digestivo· Source

• Withdrawn

  Gastrointestinal Anastomosis Using MonoPlus® Suture

  NCT04811833· Aesculap AG· Source

• Active, not recruiting

  New Clinical End-points in patients with primary Sjögren’s Syndrome: an Interventional Trial based on stratifYing patients

  NCT05113004· Phase 2· Assistance Publique Hopitaux De Paris· Source

• Completed

  Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

  NCT05052801· Phase 3· Amgen· Source

• Completed

  A study to test whether BI 706321 combined with ustekinumab helps people with Crohn's Disease

  NCT04978493· Phase 2· Boehringer Ingelheim International GmbH· Source

• Completed

  Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia

  NCT05110157· Phase 3· Neurocrine Biosciences· Source

• Completed

  A Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis

  2023-509782-20-00· Phase 2· Horizon Therapeutics Ireland Designated Activity Company· Source

• Active, not recruiting

  Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus

  NCT05039840· Phase 2· Sanofi· Source

• Completed

  Study of Efficacy, Safety and Tolerability of DFV890 in Patients With Knee Osteoarthritis

  NCT04886258· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

  NCT04987203· Phase 3· AVEO Pharmaceuticals, Inc.· Source

• Completed

  A MHealth Intervention to Improve Symptom Control in Children and Adolescents with Difficult-to-control Asthma

  NCT04166344· Lovexair Foundation· Source

• Active, not recruiting

  A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

  NCT04908202· Phase 3· Bristol-Myers Squibb· Source

• Completed

  Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)

  NCT04776447· Phase 2· Fundación GECP· Source

• Terminated

  Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee Osteoarthritis

  NCT04864392· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum Disorder

  NCT04745026· Phase 2· Jazz Pharmaceuticals· Source

Showing 50 of 93.

Conditions

Diseases this institution publishes on or runs trials for.

• Crohn's disease32 works · 10 trials
• Ulcerative colitis22 works · 10 trials
• Hidradenitis suppurativa20 works · 4 trials